Login to Your Account

MolMed Seeking $106M in IPO to Boost Cell Therapy Phase III

By Cormac Sheridan

Wednesday, February 20, 2008
One month after receiving a green light to move its cell therapy treatment for improving the outcomes of hematopoietic stem cell transplants into a Phase III clinical trial, MolMed SpA. is launching an initial public offering in which it is seeking up to €71.8 million (US$105.8 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription